- Home
- CBIO vs ARCT Comparison
CBIO vs ARCT Comparison
Compare CBIO & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBIO
- ARCT
- Stock Information
- Founded
- CBIO 2003
- ARCT 2013
- Country
- CBIO United States
- ARCT United States
- Employees
- CBIO N/A
- ARCT N/A
- Industry
- CBIO
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- CBIO
- ARCT Health Care
- Exchange
- CBIO Nasdaq
- ARCT Nasdaq
- Market Cap
- CBIO 308.0M
- ARCT 320.8M
- IPO Year
- CBIO N/A
- ARCT N/A
- Fundamental
- Price
- CBIO $12.85
- ARCT $11.91
- Analyst Decision
- CBIO Strong Buy
- ARCT Strong Buy
- Analyst Count
- CBIO 3
- ARCT 8
- Target Price
- CBIO $25.67
- ARCT $52.83
- AVG Volume (30 Days)
- CBIO 108.6K
- ARCT 355.9K
- Earning Date
- CBIO 07-31-2025
- ARCT 08-11-2025
- Dividend Yield
- CBIO N/A
- ARCT N/A
- EPS Growth
- CBIO N/A
- ARCT N/A
- EPS
- CBIO N/A
- ARCT N/A
- Revenue
- CBIO N/A
- ARCT $143,680,000.00
- Revenue This Year
- CBIO N/A
- ARCT N/A
- Revenue Next Year
- CBIO N/A
- ARCT $37.73
- P/E Ratio
- CBIO N/A
- ARCT N/A
- Revenue Growth
- CBIO N/A
- ARCT 15.38
- 52 Week Low
- CBIO $10.90
- ARCT $8.04
- 52 Week High
- CBIO $21.40
- ARCT $25.88
- Technical
- Relative Strength Index (RSI)
- CBIO N/A
- ARCT 39.31
- Support Level
- CBIO N/A
- ARCT $11.44
- Resistance Level
- CBIO N/A
- ARCT $12.37
- Average True Range (ATR)
- CBIO 0.00
- ARCT 0.83
- MACD
- CBIO 0.00
- ARCT -0.25
- Stochastic Oscillator
- CBIO 0.00
- ARCT 10.71
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.